Is oral contraceptive-induced headache dependent on patent foramen ovale? Clinical dynamics, evidence-based hypothesis and possible patient-oriented management

Chiofalo, Benito; Laganà, Antonio Simone; Imbesi, Giovanna; Vitale, Salvatore Giovanni; Catena, Ursula; Campolo, Federica; Lanzo, Gabriele; Centini, Gabriele; Triolo, Onofrio

doi:10.1016/j.mehy.2016.07.003

Cited by 9 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adolescents are an important group in need of contraceptive services, and it would be important to ensure the Preference Assessment Tool also works for young people in further work. Women and providers may also have reasons outside of pregnancy prevention for choosing or not choosing specific contraceptive methods, and this tool was not designed to capture that ( 30 – 32 ). Our preference assessment took up to 20 min to complete and required literacy, which may limit in-field use as a decision-making tool, so further research on usability and necessary adaptations for wider use are needed.…”

Section: Discussionmentioning

confidence: 99%

Developing an Assessment of Contraceptive Preferences in Botswana: Piloting a Novel Approach Using Best-Worst Scaling of Attributes

Gertz

Soffi

Mompe

et al. 2022

Front. Glob. Womens Health

View full text Add to dashboard Cite

IntroductionTo develop an attribute-based method for assessing patient contraceptive preferences in Botswana and pilot its use to explore the relationship between patient contraceptive preferences and the contraceptive methods provided or recommended to patients by clinicians.MethodsA list of contraceptive attributes was developed with input from patients, clinicians, and other stakeholders. We assessed patient preferences for attributes of contraceptives using a discrete choice “best-worst scaling” approach and a multi-attribute decision-making method that linked patient attribute preferences to actual contraceptive method characteristics. Attribute-based patient method preferences and clinician recommendations were compared in 100 women seeking contraceptive services, and 19 clinicians who provided their care. For 41 of the patients, the short-term reliability of their preference scores was also examined.ResultsFor 57 patients who wanted more children in the future, the degree of concordance between patients and clinicians was 7% when comparing the top attribute-based contraceptive preference for each woman with the clinician-provided/recommended method. When the top two model-based preferred contraceptive methods were considered, concordance was 28%. For 43 women who did not want more children, concordance was 0% when using the patient's model-based “most-preferred” method, and 14% when considering the top two methods. Assessment of the short-term reliability of preference scores yielded an intraclass correlation coefficient of 0.93.ConclusionsA best-worst scaling assessment of attributes of contraceptives was designed and piloted in Botswana as a Contraceptive Preference Assessment Tool. The preference assessment was found to have high short-term reliability, which supports its potential use as a measurement tool. There was very low concordance between women's attribute-based contraceptive preferences and their clinician's provision/recommendations of contraceptive methods. Using such a preference assessment tool could encourage greater patient involvement and more tailored discussion in contraceptive consultations.

show abstract

Section: Discussionmentioning

confidence: 99%

Developing an Assessment of Contraceptive Preferences in Botswana: Piloting a Novel Approach Using Best-Worst Scaling of Attributes

Gertz

Soffi

Mompe

et al. 2022

Front. Glob. Womens Health

View full text Add to dashboard Cite

show abstract

“…Regarding exogenous hormone use, history of OC use or maternal hormone therapy after menopause was investigated in this study. OCs (some of the most frequently prescribed medication types for women) regulate the natural female cycle through disruption of the hypothalamic-pituitary-ovarian axis by elevating the oestradiol concentration of the body; their impact on sensory perception or cognition have been reported 20,21 . Previous studies that suggested OCs affect the higher olfactory performance reported that the dose of oestradiol and duration of OC use are essential factors that influence the effect 22,23 .…”

Section: Discussionmentioning

confidence: 99%

Association between subjective olfactory dysfunction and female hormone-related factors in South Korea

Lee

Choi

Lee

et al. 2019

Sci Rep

View full text Add to dashboard Cite

An association between olfactory dysfunction and female hormone level has been reported; however, no previous studies have investigated the correlation with life-long female hormone exposure. The aim of this study was to estimate the association between subjective olfactory dysfunction and various endogenous and exogenous female hormone-related factors including age at menarche and menopause, number of pregnancies and deliveries, age at first and last delivery, duration of breastfeeding, use of oral contraceptives, and use of hormone therapy. The study analysed a total of 3863 female participants using data from the Korean National Health and Nutrition Examination Survey V (2010–2012). The prevalence of olfactory dysfunction was 3.5% for premenopausal participants and 6.2% for postmenopausal women. Among premenopausal women (compared to women breastfed less than 12 months), the 12–24-month group (OR = 4.690, 95% CI = 1.431–15.369) and the 25–48-month group (OR = 6.548, 95% CI = 1.758–24.394) had higher rates of olfactory dysfunction. In postmenopausal women, starting menopause at a younger age was positively associated with olfactory dysfunction (OR = 0.939, 95% CI = 0.887–0.993). These data suggest that a longer duration of endogenous oestrogen deprivation is associated with subjective olfactory dysfunction.

show abstract

“…Also excluded were patients who had undergone surgical treatment for endometriosis by laparotomy or laparoscopy within 2 months prior to the baseline observation phase and those needing analgesics regularly for therapeutic objectives other than relief from the pelvic pain associated with dysmenorrhea during this study (occasional use permitted). Any patient with a disease or condition that worsened under hormonal treatment according to the opinion of the investigator, including hypertension, valvular or coronary heart disease, cerebrovascular disease, thrombophlebitis, predisposition to thrombosis,15 hepatic dysfunction (including a history of liver disease or herpes during pregnancy), severe renal insufficiency, diabetes, dyslipidemia, estrogen-dependent tumors, migraine,16 otosclerosis, uncontrolled thyroid disorder, and clinical depression, or who were scheduled for imminent major surgery or who had any condition, or used any medication, that might interfere with the conduct of study or the interpretation of results, was excluded.…”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study

Momoeda

Kondo

Elliesen

et al. 2017

IJWH

View full text Add to dashboard Cite

BackgroundDysmenorrhea is a common condition in women, which is characterized by menstrual pain. Low-dose estrogen/progestin combined oral contraceptives have been shown to reduce the severity of dysmenorrhea symptoms, and a 28-day cyclic regimen of ethinylestradiol/drospirenone (28d regimen) is approved for this indication in Japan.AimThe aim of this study was to assess the safety and efficacy of a flexible extended regimen of ethinylestradiol/drospirenone (flexible regimen) in Japanese women with dysmenorrhea.MethodsThis multicenter, open-label study was performed in Japanese women with dysmenorrhea who, after a baseline observational phase, were randomized to receive ethinylestradiol 20 μg/drospirenone 3 mg in a flexible regimen (one tablet each day for 24–120 days followed by a 4-day tablet-free interval) or in the standard 28d regimen (one tablet each day for 24 days, followed by 4 days of placebo tablets for six cycles). The primary endpoint was the number of days with dysmenorrhea of at least mild intensity over a 140-day evaluation period. Dysmenorrhea scores, bleeding patterns, and other pain-related parameters were also assessed.ResultsA total of 216 women (mean age 29.7 years) were randomized to the flexible regimen (n=108) or 28d regimen (n=108) and 212 were included in the full analysis sets (flexible regimen, n=105; 28d regimen, n=107). Women in the flexible-regimen group reported a mean of 3.4 fewer days with dysmenorrheic pain than women in the 28d-regimen group, with similar decreases in disease severity reported in both treatment groups. According to the investigators, 64.8% and 59.4% of women in the flexible-regimen and 28d-regimen treatment groups had “very much improved” or “much improved” disease, while 54.3% and 50.9% of patients reported being “very much satisfied” or “much satisfied” with their treatment, respectively.ConclusionIn Japanese women with dysmenorrhea, a flexible extended regimen of ethinylestradiol/drospirenone decreased the number of days with dysmenorrheic pain versus the traditional 28d regimen.

show abstract

Is oral contraceptive-induced headache dependent on patent foramen ovale? Clinical dynamics, evidence-based hypothesis and possible patient-oriented management

Cited by 9 publications

References 20 publications

Developing an Assessment of Contraceptive Preferences in Botswana: Piloting a Novel Approach Using Best-Worst Scaling of Attributes

Developing an Assessment of Contraceptive Preferences in Botswana: Piloting a Novel Approach Using Best-Worst Scaling of Attributes

Association between subjective olfactory dysfunction and female hormone-related factors in South Korea

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study

Contact Info

Product

Resources

About